logo
Former Virgin Money chief Gadhia to chair energy supplier Ovo

Former Virgin Money chief Gadhia to chair energy supplier Ovo

Yahoo10-07-2025
A former boss of Virgin Money boss is joining Britain's fourth-biggest home energy supplier as it explores options including a merger with one of its biggest rivals.
Sky News has learnt that Dame Jayne-Anne Gadhia, who now holds a string of chairmanships, will become independent chair of Ovo as part of a boardroom shake-up at its parent company.
Sources said her appointment would be announced later on Thursday, alongside those of Miguel Gaspar Silva and Andy Cox to the board of Kaluza, Ovo Group's technology arm.
Money blog: Top chef reveals thing he hates about customers
As part of the overhaul, Justin King, the former J Sainsbury chief, is stepping down as group chairman, insiders said.
Dame Jayne-Anne's appointment comes at a crucial time for Ovo, which Sky News revealed this month is in the early stages of merger talks with Scottish Power.
It is also separately running a process with potential investors to secure an additional £300m of financial backing.
In a statement released to Sky News, Ovo said Dame Jayne-Anne's "understanding of consumer markets and regulatory frameworks will be instrumental in guiding OVO's continued evolution and navigating the dynamic energy landscape".
The Kaluza board appointments are designed to help the Ovo-controlled division accelerate its international expansion.
Last weekend, Sky News revealed that Kraken Technologies, which is owned by rival Octopus Energy, is being prepared for a demerger, which could value it at about £10bn.
Kaluza recently bought Beige Technologies, an Australian energy software specialist, in order to strengthen its presence in the Asia-Pacific region.
Founded by Stephen Fitzpatrick, the entrepreneur who now owns London's Kensington Roof Gardens, Ovo's shareholders include the private equity firm Mayfair Equity Partners, Morgan Stanley Investment Management and Mitsubishi Corporation, the Japanese conglomerate.Under Mr Fitzpatrick, who launched Ovo in 2009, the company positioned itself as a challenger brand offering superior service to the industry's established players.Ovo's transformational moment came in 2020, when it bought the retail supply arm of SSE, transforming it overnight into one of Britain's leading energy companies.
Read more from Sky News:Its growth has not been without difficulties, however, particularly in relation to its challenged relationship with Ofgem and a torrent of customer complaints about overcharging.The group is now run by David Buttress, who was briefly Boris Johnson's cost-of-living tsar after leaving the top job at Just Eat, as its chief executive.Key to Ovo's longer-term valuation will be the performance of Kaluza, which was set up to license software to other energy suppliers and provides customers with smart electric vehicle charging and heat pumps, as well as intelligent energy solutions to commercial customers.Ovo announced last year that AGL Energy, one of Australia's biggest energy suppliers, had bought a 20% stake in Kaluza at a $500m (£395m) valuation.
The British energy company has also entered the electric vehicle car charging sector under the brand Charge Anywhere, adding tens of thousands of public charging points across the UK.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Vertiv Buys Rack Solutions Provider To Enhance AI Infrastructure
Vertiv Buys Rack Solutions Provider To Enhance AI Infrastructure

Yahoo

time2 minutes ago

  • Yahoo

Vertiv Buys Rack Solutions Provider To Enhance AI Infrastructure

Vertiv Inc. (NYSE:VRT) announced Thursday that it has agreed to acquire Great Lakes Data Racks & Cabinets for $200 million, a move designed to strengthen its leadership in the expanding AI and edge computing markets. The transaction is expected to close in the third quarter of 2025. This acquisition will enhance Vertiv's ability to deliver pre-engineered, AI-ready rack solutions for data centers, enterprise, edge, and hyperscale computing markets. Great Lakes, established in 1985, operates manufacturing facilities in the U.S. and Europe. It specializes in customizable data racks, seismic cabinets, and cable management solutions. Also Read: Vertiv's CEO, Gio Albertazzi, noted that this deal will not only streamline sourcing and improve operational efficiency but also increase scalability for AI and edge computing applications. He emphasized, 'Great Lakes strengthens Vertiv's position as a premier technology solutions provider in the AI infrastructure environment.' By integrating Great Lakes' expertise, Vertiv will be able to offer faster deployment, more efficient sourcing, and enhanced solutions for critical digital infrastructure. The acquisition is also expected to generate significant cost synergies and cross-selling opportunities. The deal is still subject to regulatory approvals under the Hart-Scott-Rodino Antitrust Improvements Act. Vertiv held cash and cash equivalents of $1.467 billion as of March 31, 2025. Price Action: VRT shares are trading higher by 4.78% to $131.39 at last check Thursday. Read Next:Photo via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article Vertiv Buys Rack Solutions Provider To Enhance AI Infrastructure originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

National Fuel Schedules Third Quarter Fiscal 2025 Earnings Conference Call
National Fuel Schedules Third Quarter Fiscal 2025 Earnings Conference Call

Yahoo

time2 minutes ago

  • Yahoo

National Fuel Schedules Third Quarter Fiscal 2025 Earnings Conference Call

WILLIAMSVILLE, N.Y., July 17, 2025 (GLOBE NEWSWIRE) -- National Fuel Gas Company (NYSE: NFG) today announced it will release its third quarter fiscal 2025 earnings results on Wednesday, July 30, 2025 after market close. A conference call to discuss the results will be held on Thursday, July 31, 2025 beginning at 9:00 a.m. ET. Prepared remarks from the executive team are planned for approximately 20 minutes followed by a question and answer session. All participants must pre-register to join this conference using the . A webcast link to the conference call will be provided under the Events Calendar on the NFG Investor Relations website at A replay will be available following the call through the end of the day, Thursday, August 7, 2025. To access the replay, dial 1-866-813-9403 and provide Access Code 592578. National Fuel is a diversified energy company headquartered in Western New York that operates an integrated collection of natural gas assets across four business segments: Exploration & Production, Pipeline & Storage, Gathering, and Utility. Additional information about National Fuel is available at For additional information, contact: Natalie Fischer, Director of Investor Relations (716) 857-7315Kathryn Nikisch-Hoffman, Equity Plan Administrator (716) 857-7340Karen Merkel, Media Contact (716) 857-7654Email: nfg_investor_relations@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Nontuberculous Mycobacteria (NTM) Opportunity Assessment and Forecast to 2033 Featuring Janssen, Novartis, Meiji Seika Pharma, Insmed, Daiichi Sankyo, MannKind, Paratek, Nobelpharma, GSK, Pfizer
Nontuberculous Mycobacteria (NTM) Opportunity Assessment and Forecast to 2033 Featuring Janssen, Novartis, Meiji Seika Pharma, Insmed, Daiichi Sankyo, MannKind, Paratek, Nobelpharma, GSK, Pfizer

Yahoo

time2 minutes ago

  • Yahoo

Nontuberculous Mycobacteria (NTM) Opportunity Assessment and Forecast to 2033 Featuring Janssen, Novartis, Meiji Seika Pharma, Insmed, Daiichi Sankyo, MannKind, Paratek, Nobelpharma, GSK, Pfizer

Comprehensive analysis of the NTM therapeutics market: Overview of disease, epidemiology, treatment options, and forecast from 2023-2033 for 7 major markets. Insights include pipeline trends, market drivers, competitive landscape, and strategies for growth and investment in the NTM market. Dublin, July 17, 2025 (GLOBE NEWSWIRE) -- The "Nontuberculous Mycobacteria (NTM): Opportunity Assessment and Forecast" report has been added to report provides an assessment of the NTM therapeutics market including disease overview, epidemiology, current treatment options, unmet needs and opportunities, R&D strategies, pipeline assessment, and market refers to infection with a group of bacteria within the Mycobacterium genus, which excludes Mycobacterium tuberculosis (tuberculosis) and Mycobacterium leprae (leprosy). NTM infections are noncontagious, opportunistic infections that cause a wide range of clinical disease in patients with pre-existing health conditions or compromised immune systems.). In terms of global burden, NTM lung disease is relatively uncommon. It is suggested that host defense mechanisms in most healthy individuals are sufficient to prevent or suppress NTM infection. Patients who develop NTM lung disease likely have susceptibility factors such as pre-existing comorbidities that make them vulnerable to these Highlights Report deliverables include a Pdf report and an Excel-based forecast model Forecast includes the 7 major markets (7MM) Forecast covers the period 2023-2033 Scope Overview of NTM, including classification, epidemiology, diagnostic and treatment paradigms. Annualized NTM therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2023 to 2033. Key topics covered include assessment of marketed therapies and pipeline agents, unmet needs, pipeline assessment and market outlook for the US, 5EU, and Japan over the 10-year forecast period. Pipeline analysis: Emerging novel trends under development, and detailed analysis of late-stage pipeline drugs. Analysis of the current and future market competition in the 7MM NTM therapeutics market. Insightful review of the key industry drivers and barriers. Reasons to Buy Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipelines. Develop business strategies by understanding the trends shaping and driving the 7MM NTM therapeutics market. Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the NTM therapeutics market in the future. Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. Key Topics Covered: 1. Preface1.1. Contents1.2. Abbreviations1.3. Related Reports2. Executive Summary3. Disease Overview3.1. Overview of NTM3.2. NTM Market SWOT Analysis3.3. Classification of NTM3.4. NTM Risk Factors4. Epidemiology4.1. Diagnosed Incident Cases NTM, N, Both Sexes, 2023-334.2. Diagnosed Prevalent Cases of NTM, Both Sexes, N, 2023-334.3. Diagnosed Incident Cases of NTM, PNTM, and DNTM, Both Sexes, N, 20234.4. Diagnosed Prevalent Cases of NTM, PNTM, and DNTM, Both Sexes, N, 20234.5. Sources and Methodology for Diagnosed Incident Cases of NTM, PNTM, and DNTM4.6. Sources and Methodology for Diagnosed Prevalent Cases of NTM, PNTM and DNTM4.7. Sources and Methodology for Diagnosed Incident and Prevalent Cases of NTM4.8. Sources and Methodology for Diagnosed Incident and Prevalent Cases of PNTM4.9. Sources and Methodology for Diagnosed Incident and Prevalent Cases of DNTM5. Current Treatment Options5.1. PNTM Diagnostic Paradigm5.2. Treatment Paradigm5.3. Current Treatment Options6. Unmet Needs and Opportunities6.1. Unmet Needs in NTM6.2. New Therapeutic Options with Improved Efficacy6.3. Improved Diagnostic Methods6.4. Improved Clinical Trials7. R&D Strategies7.1. Trends in Clinical Trial Design in NTM7.2. Trends in Deal-Making in NTM8. Pipeline Assessment8.1. NTM Pipeline Overview8.2. Late-Stage Pipeline Products for NTM8.3. NTM Clinical Trials (Phase II/III) Overview9. Market Outlook9.1. NTM Market Forecast9.2. PNTM Market Forecast9.3. DNTM Market Forecast9.4. Market Drivers and Barriers10. Appendix Competitive Landscape Janssen Novartis AG Meiji Seika Pharma Co Ltd Insmed Inc Daiichi Sankyo Co Ltd MannKind Corp Paratek Pharmaecuticals Inc Nobelpharma Co Ltd GlaxoSmithKline AG Pfizer For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store